Affymax Anticipates Broad Opportunity For Omontys With Both Small And Large Dialysis Providers

With FDA’s March 27 approval of peginesatide to prevent anemia in CKD patients on dialysis, Affymax will focus initially on marketing to smaller, price-conscious dialysis providers. But the biotech also expects to do business with Fresenius and, to a lesser degree, Davita.